Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity

Li,Shouyong; Wei,Yanlei

doi:10.3892/ol.2018.8482

Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity

Authors:
- Shouyong Li
- Yanlei Wei
View Affiliations

Affiliations: Department of Clinical Laboratory, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China, Department of Pharmacy, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China
Published online on: April 13, 2018 https://doi.org/10.3892/ol.2018.8482
Pages: 9572-9576
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of high mobility group box 1 (HMGB1), breast cancer susceptibility gene 1 (BRCA1) and P62 in ovarian cancer was investigated to explore its association with chemotherapy sensitivity in ovarian cancer patients. Tumor tissues and para-carcinoma normal tissues of 60 ovarian cancer patients hospitalized in Department of Surgery in Dongying Hospital from June, 2012 to June, 2015 were collected. Reverse transcription‑quantitative polymerase chain reaction (RT-qPCR) was used to detect the mRNA expression levels of HMGB1, BRCA1 and P62 in tumor and para-carcinoma normal tissues. Moreover, immunohistochemistry was used to detect the protein expression of HMGB1, BRCA1 and P62 in tumor tissues and para-carcinoma normal tissues. The cancer tissue specimens were divided into the chemotherapy resistance group and sensitivity group through the in vitro resin droplet experiment to analyze the association of the expression of HMGB1, BRCA1 and P62 in epithelial ovarian cancer with chemotherapy resistance of patients. The RT-qPCR results showed that the expression of HMGB1, BRCA1 and P62 in ovarian cancer tissues at the mRNA level was significantly higher than that in para-carcinoma normal tissues. Immunohistochemical results showed that the positive expression levels of HMGB1, BRCA1 and P62 in ovarian carcinoma tissue were 61.67% (37/60), 76.33% (47/60) and 71.67% (43/60), respectively, while the positive expression levels of HMGB1, BRCA1 and P62 in para-carcinoma normal tissues were 13.33% (8/60), 8.33% (5/60) and 11.67% (7/60), respectively, and the differences were statistically significant (P<0.05). In vitro resin droplet experiment revealed that 38 out of 60 ovarian cancer patients were drug resistant and 22 patients were sensitive to the therapy. The analysis of the association with chemotherapy sensitivity revealed that the positive expression of HMGB1, BRCA1 and P62 was associated with the drug resistance of ovarian cancer patients. The positive expression of HMGB1, BRCA1 and P62 was associated with chemotherapy sensitivity of ovarian cancer patients. Therefore, HMGB1, BRCA1 and P62 may be molecular markers for the prediction of chemotherapy sensitivity of ovarian cancer patients.

View Figures

View References

1	Wang Y, Liu P, Qiu L, Sun Y, Zhu M, Gu L, Di W and Duan Y: Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials. 34:4068–4077. 2013. View Article : Google Scholar : PubMed/NCBI
2	Wu YJ, Neuwelt AJ, Muldoon LL and Neuwelt EA: Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma. Anticancer Res. 33:2391–2400. 2013.PubMed/NCBI
3	Ong PS, Chan SY and Ho PC: Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As₂O₃ and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR. Eur J Pharm Sci. 45:367–378. 2012. View Article : Google Scholar : PubMed/NCBI
4	Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta. 1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
5	Wu D, Ding Y, Wang S, Zhang Q and Liu L: Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol. 216:167–175. 2008. View Article : Google Scholar : PubMed/NCBI
6	Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B and Yu H: Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol. 100:330–337. 2006. View Article : Google Scholar : PubMed/NCBI
7	Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ and Purohit A: Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer. 102:316–324. 2010. View Article : Google Scholar : PubMed/NCBI
8	Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH and Harkin DP: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 13:7413–7420. 2007. View Article : Google Scholar : PubMed/NCBI
9	Moscat J, Diaz-Meco MT and Wooten MW: Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci. 32:95–100. 2007. View Article : Google Scholar : PubMed/NCBI
10	Kobayashi H, Tanisaka K, Doi O, Kodama K, Higashiyama M, Nakagawa H, Miyake M, Taki T, Hara S, et al: An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol. 11:449–455. 1997.PubMed/NCBI
11	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
12	Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, Miyake K, Koyamatsu Y, Akiya T, Iwabuchi H, Muroya T, et al: Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell. 14:305–315. 2001.PubMed/NCBI
13	Takano M, Kudo K, Goto T, Yamamoto K, Kita T and Kikuchi Y: Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. Hum Cell. 14:267–271. 2001.PubMed/NCBI
14	Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Lotze MT, et al: HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia. 25:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
15	Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
16	Garvin AM, Attenhofer-Haner M and Scott RJ: BRCA1 and BRCA2 mutation analysis in 86 early onset breast/ovarian cancer patients. J Med Genet. 34:990–995. 1997. View Article : Google Scholar : PubMed/NCBI
17	Greggio E, Lewis PA, van der Brug MP, Ahmad R, Kaganovich A, Ding J, Beilina A, Baker AK and Cookson MR: Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J Neurochem. 102:93–102. 2007. View Article : Google Scholar : PubMed/NCBI
18	Haugarvoll K, Toft M, Ross OA, White LR, Aasly JO and Farrer MJ: Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. Neurosci Lett. 416:299–301. 2007. View Article : Google Scholar : PubMed/NCBI
19	Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T and Liu B: ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 8:972008. View Article : Google Scholar : PubMed/NCBI
20	Yu H, Su J, Xu Y, Kang J, Li H, Zhang L, Yi H, Xiang X, Liu F and Sun L: p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. J Eur Cancer. 47:1585–1594. 2011. View Article : Google Scholar